Bispecific EGF-IGF-LDP-AE at 0.2 mg/kg and 0.4 mg/kg yielded tumor growth inhibition of 69.7% and 80.5%, respectively, whereas the lidamycin-treated group at maximum tolerated dosage (0.05 mg/kg) only showed inhibition rate of 59.4% (p < 0.01). Here, EGF is linked to neoplasm.